Source of Support: None, Conflict of Interest: None
Immunotherapy is used as a method of treatment in patients with bronchial asthma, but its usefulness is limited to highly selected patients. Measurement of IgG antibodies act as indicators for improvement of patients after hyposensitisation. Skin test responses both immediate and late phase cutaneous reactions were also used as a parameter to evaluate the effect of immunotherapy (IT). Fifty patients of perennial bronchial asthma of confirmed diagnosis were selected and given immunotherapy. Twenty one (42%) of the patients showed reduction of the skin test response for both immediate and late phase cutaneous reaction (LPCR). Twenty nine (58%) showed reduction for LPCR alone and none showed reduction for immediate response alone. Immediate reaction after immunotherapy was not significant at p<0.05 and LPCR is significant at p <0.05. It is observed that the patients who showed reduction in the skin test reaction also showed a reduction in the symptoms and drug score. Results indicate that LPCR can be a better indicator for the improvement of immunotherapy.